Your Hospital Isn’t Just a Number: Reclaiming Local Autonomy in Rural Healthcare 
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (“Assembly Bio”) (Nasdaq: ASMB), a biotechnology company...
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected...
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a...
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at...
Vaxart CEO Issues Letter to Stockholders
- Management Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on September 4, 2025...
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed...
Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma
SHANGHAI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading...
Sotera Health Reports Strong Second-Quarter and First-Half 2025 Results
Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis(1), compared to Q2 2024Q2...
Spectral Medical Announces Second Quarter and Provides Corporate Update
Topline Tigris results expected to be released around mid-August 2025 TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc....
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the...
Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
NEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a...
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT global pivotal study (“BACKBEAT study”), resulting in an estimated...
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance
Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on...
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments
Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company’s guidance...
Sanuwave Announces Q2 FY2025 Financial Results
Q2 2025 revenues were $10.2 million, up 42% from $7.2 million in Q2 2024. This represents the highest Q2 quarterly...
Vistin Pharma ASA: Invitation to Q2 2025 conference call
Oslo, Norway, 08 August 2025 Vistin Pharma ASA will release its second quarter and YTD 2025 results on Friday 15th...
Coloplast A/S – 9M 2024/25 Earnings Release – Invitation to conference call on 19 August 2025 at 11.00am CEST
Tuesday, 19 August 2025 at 11.00 - 12.00h CESTIn connection with the publication of Coloplast’s interim financial results for 9M...
Sai Life Sciences Limited Reports Revenue growth of 77% YoY
Q1FY26 Revenue at ₹496 Cr; EBITDA at ₹125 Cr; Net Profit at ₹60 CrHYDERABAD, India, Aug. 08, 2025 (GLOBE NEWSWIRE)...
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
Tokyo, Japan and Cambridge, UK, 8 August 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update...
HK-listed IVD Medical Invests HK$149M in Ethereum through HashKey Exchange
HONG KONG, Aug. 8, 2025 /PRNewswire/ -- HashKey Exchange, Hong Kong's largest * licensed virtual asset trading platform, has entered...